X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.
The company said it expects to save $30 million to $35 million annually and have enough funds to support operations through H1 2026. The workforce reductions will be completed by Q1 2025.
X4 said it is restructuring its workforce and capital spending to focus on advancing mavorixafor for chronic neutropenia and promoting Xolremdi, or mavorixafor, in the US for warts, hypogammaglobulinemia, infections and myelokathexis syndrome.
The company is also pausing pre-clinical drug programs and scaling down the US commercial field team.
Shares of X4 fell 6% in recent trading.
Price: 0.58, Change: -0.04, Percent Change: -6.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.